The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells

eLife

Volumn 4, Issue MAY, 2015, Pages 1-27

  Khor, Bernard ^a,b,c   Gagnon, John D ^b   Goel, Gautam ^a   Roche, Marly I ^c   Conway, Kara L ^a,b   Tran, Khoa ^a   Aldrich, Leslie N ^b,d   Sundberg, Thomas B ^b   Paterson, Alison M ^a   Mordecai, Scott ^c   Dombkowski, David ^c   Schirmer, Melanie ^b   Tan, Pauline H ^a   Bhan, Atul K ^c   Roychoudhuri, Rahul ^e   Restifo, Nicholas P ^e   O’Shea, John J ^f   Medoff, Benjamin D ^c   Shamji, Alykhan F ^b   Schreiber, Stuart L ^b,d   Sharpe, Arlene H ^a   Shaw, Stanley Y ^a   Xavier, Ramnik J ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; CISAPRIDE; DYRK1A PROTEIN; GAMMA INTERFERON; HARMINE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; RAPAMYCIN; SERTACONAZOLE; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TH17 CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE TECHNIQUE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; HARMINE; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84930671852     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.05920     Document Type: Article

References (84)

1. Aranda S, Laguna A, de la Luna S. 2011. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. The FASEB Journal 25:449-462. doi: 10.1096/fj.10-165837.
2. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. 2013. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451-455. doi: 10.1038/nature12726.
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. The Biochemical Journal 408:297-315. doi: 10.1042/ BJ20070797.
4. Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, Xavier RJ. 2010. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood 115:5376-5384. doi: 10.1182/blood-2010-01-263855.
5. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, Sefik E, Tan TG, Wagers AJ, Benoist C, Mathis D. 2013. A special population of regulatory T cells potentiates muscle repair. Cell 155:1282-1295. doi: 10.1016/j. cell.2013.10.054.
6. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Andrade EO, Mash DC. 1999. Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 65:243-256. doi: 10.1016/S0378-8741(98)00168-8.
7. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY. 2011. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cellmediated inflammation. Immunity 34:566-578. doi: 10.1016/j.immuni.2011.03.018.
8. Christodoulou K,Wiskin AE, Gibson J, TapperW,Willis C, Afzal NA, Upstill-Goddard R, Holloway JW, Simpson MA, Beattie RM, Collins A, Ennis S. 2013. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. Gut 62:977-984. doi: 10.1136/gutjnl-2011-301833.
9. Collison LW, Vignali DA. 2011. In vitro Treg suppression assays. Methods in Molecular Biology 707:21-37. doi: 10.1007/978-1-61737-979-6_2.
10. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. 2007. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. The Journal of Experimental Medicine 204:1757-1764. doi: 10.1084/jem.20070590.
11. Corona JA, Davis RD, Kedia SB, Mitchell MB. 2010. Expedited development through parallel reaction screening: application to PTC-mediated knoevenagel condensation. Organic Process Research & Development 14:712-715. doi: 10.1021/op100026u.
12. Cretney E, Kallies A, Nutt SL. 2013. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends in Immunology 34:74-80. doi: 10.1016/j.it.2012.11.002.
13. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ. 2008. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 29:114-126. doi: 10.1016/j. immuni.2008.05.010.
14. Darce J, Rudra D, Li L, Nishio J, Cipolletta D, Rudensky AY, Mathis D, Benoist C. 2012. An N-terminal mutation of the foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Immunity 36:731-741. doi: 10.1016/j. immuni.2012.04.007.
15. De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, Bhan AK, Terhorst C. 2000. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 119:715-723. doi: 10.1053/gast.2000.16485.
16. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF. 2012. Safety and efficacy of antigen-specific regulatory t-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143:1207-1217. e1-2. doi: 10.1053/j.gastro.2012.07.116.
17. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research 30:207-210. doi: 10.1093/nar/30.1.207.
18. Edozie FC, Nova-Lamperti EA, Povoleri GA, Scottà C, John S, Lombardi G, Afzali B. 2014. Regulatory T-cell therapy in the induction of transplant tolerance: the issue of subpopulations. Transplantation 98:370-379. doi: 10.1097/TP.0000000000000243.
19. Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D Trappe J, Rauch U, Bracher F, Knapp S. 2011. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chemistry & Biology 18:67-76. doi: 10.1016/j.chembiol.2010.11.009.
20. Feuerer M, Hill JA, Kretschmer K, von Boehmer H, Mathis D, Benoist C. 2010. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proceedings of the National Academy of Sciences of USA 107:5919-5924. doi: 10.1073/pnas.1002006107.
21. Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Fassett MS, Gazit R, Adoro S, Glimcher L, Chan S, Kastner P, Rossi D, Collins JJ, Mathis D, Benoist C. 2012. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nature Immunology 13:972-980. doi: 10.1038/ni.2420.
22. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450. doi: 10.1038/nature12721.
23. Ghosh S, Koralov SB, Stevanovic I, Sundrud MS, Sasaki Y, Rajewsky K, Rao A, Müller MR. 2010. Hyperactivation of nuclear factor of activated T cells 1 (NFAT1) in T cells attenuates severity of murine autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of USA 107:15169-15174. doi: 10.1073/ pnas.1009193107.
24. Goel G, Conway KL, Jaeger M, Netea MG, Xavier RJ. 2014. Multivariate inference of pathway activity in host immunity and response to therapeutics. Nucleic Acids Research 42:10288-10306. doi: 10.1093/nar/gku722.
25. Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Filbey KJ, Finney CA, Greenwood EJ, Knox DP Wilson MS, Belkaid Y, Rudensky AY, Maizels RM. 2010. Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway. The Journal of Experimental Medicine 207: 2331-2341. doi: 10.1084/jem.20101074.
26. Gu AD, Wang Y, Lin L, Zhang SS, Wan YY. 2012. Requirements of transcription factor Smad-dependent and-independent TGF-β signaling to control discrete T-cell functions. Proceedings of the National Academy of Sciences of USA 109:905-910. doi: 10.1073/pnas.1108352109.
27. Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S, Okamura H, Bolton D, Feske S, Hogan PG, Rao A. 2006. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441: 646-650. doi: 10.1038/nature04631.
28. Hall JA, Cannons JL, Grainger JR, Dos Santos LM, Hand TW, Naik S, Wohlfert EA, Chou DB, Oldenhove G Robinson M, Grigg ME, Kastenmayer R, Schwartzberg PL, Belkaid Y. 2011. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity 34:435-447. doi: 10.1016/j.immuni.2011.03.003.
29. Haxhinasto S, Mathis D, Benoist C. 2008. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. The Journal of Experimental Medicine 205:565-574. doi: 10.1084/jem.20071477.
30. Herman AE, Freeman GJ, Mathis D, Benoist C. 2004. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. The Journal of Experimental Medicine 199:1479-1489. doi: 10.1084/jem.20040179.
31. Hermann-Kleiter N, Baier G. 2010. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood 115: 2989-2997. doi: 10.1182/blood-2009-10-233585.
32. Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. 2007. Foxp3 transcriptionfactor- dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27: 786-800. doi: 10.1016/j.immuni.2007.09.010.
33. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, Mathis D, Benoist C. 2008. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 29:758-770. doi: 10.1016/j.immuni.2008.09.018.
34. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR. 2011. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472:486-490. doi: 10.1038/nature09978.
35. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, Sharpe AH, Quintana FJ, Mathis D, Benoist C, Hafler DA, Kuchroo VK. 2014. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40:569-581. doi: 10.1016/j.immuni. 2014.02.012.
36. Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of differentiation and function. Annual Review of Immunology 30:531-564. doi: 10.1146/annurev.immunol.25.022106.141623.
37. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J,Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G,Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao HInternational IBD Genetics Consortium (IIBDGC) Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119-124. doi: 10.1038/nature11582.
38. Kagami SI, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, Hirose K, Watanabe N, Iwamoto I, Nakajima H. 2009. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. International Immunology 21:679-689. doi: 10.1093/intimm/dxp037.
39. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. 2007. Relating protein pharmacology by ligand chemistry. Nature Biotechnology 25:197-206. doi: 10.1038/nbt1284.
40. Keramati AR, Fathzadeh M, Go GW, Singh R, Choi M, Faramarzi S, Mane S, Kasaei M, Sarajzadeh-Fard K, Hwa J, Kidd KK, Babaee Bigi MA, Malekzadeh R, Hosseinian A, Babaei M, Lifton RP, Mani A. 2014. A form of the metabolic syndrome associated with mutations in DYRK1B. The New England Journal of Medicine 370: 1909-1919. doi: 10.1056/NEJMoa1301824.
41. Khor B, Gardet A, Xavier RJ. 2011. Genetics and pathogenesis of inflammatory bowel disease. Nature 474: 307-317. doi: 10.1038/nature10209.
42. Kim YC, Kim KK, Shevach EM. 2010. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology 130:484-493. doi: 10.1111/j.1365-2567.2010.03269.x.
43. KleinewietfeldM,Manzel A, Titze J, Kvakan H, Yosef N, Linker RA,Muller DN, Hafler DA. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496:518-522. doi: 10.1038/nature11868.
44. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP III, Armand P, Cutler C, Ho VT, Treister NS Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. 2011. Interleukin-2 and regulatory T cells in graft-versus-host disease. The New England Journal of Medicine 365:2055-2066. doi: 10.1056/NEJMoa1108188.
45. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. 2006. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935. doi: 10.1126/science.1132939.
46. Lepagnol-Bestel AM, Zvara A, Maussion G, Quignon F, Ngimbous B, Ramoz N, Imbeaud S, Loe-Mie Y, Benihoud K, Agier N, Salin PA, Cardona A, Khung-Savatovsky S, Kallunki P, Delabar JM, Puskas LG, Delacroix H, Aggerbeck L, Delezoide AL, Delattre O, Gorwood P, Moalic JM, Simonneau M. 2009. DYRK1A interacts with the REST/ NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Human Molecular Genetics 18:1405-1414. doi: 10.1093/hmg/ddp047.
47. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. 2008. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nature Immunology 9:632-640. doi: 10.1038/ni.1607.
48. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ. Diabetes TrialNet and the Immune Tolerance Network. 2012. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 61:2340-2348. doi: 10.2337/db12-0049.
49. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, CôtéS, Shoichet BK, Urban L. 2012. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486:361-367. doi: 10.1038/nature11159.
50. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. The Journal of Experimental Medicine 205:1551-1557. doi: 10.1084/jem.20080218.
51. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317:256-260. doi: 10.1126/science.1145697.
52. Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, Sakoda E, Ikebe D, Yamamoto M, Igarashi K. 2004. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 429:566-571. doi: 10.1038/nature02596.
53. Nolting J, Daniel C, Reuter S, Stuelten C, Li P, Sucov H, Kim BG, Letterio JJ, Kretschmer K, Kim HJ, von Boehmer H. 2009. Retinoic acid can enhance conversion of naive into regulatory T cells independently of secreted cytokines. The Journal of Experimental Medicine 206:2131-2139. doi: 10.1084/jem.20090639.
54. Odegaard JI, Chawla A. 2013. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339:172-177. doi: 10.1126/science.1230721.
55. Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T, Kii I, Yoshida M, Ikura T, Onogi H, Shibuya H, Hosoya T, Ito N Hagiwara M. 2010. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nature Communications 1:86. doi: 10.1038/ncomms1090.
56. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, DieudéP, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop MRACI consortiumGARNET consortiumEyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. 2014. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376-381. doi: 10.1038/nature12873.
57. Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, Mortara L, Accolla RS, Nespoli L. 2012. Down syndrome, autoimmunity and T regulatory cells. Clinical and Experimental Immunology 169:238-243. doi: 10.1111/j.1365-2249.2012.04610.x.
58. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. International Immunology 5: 1461-1471. doi: 10.1093/intimm/5.11.1461.
59. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP. 2013. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 498: 506-510. doi: 10.1038/nature12199.
60. Ruan Q, Kameswaran V, Tone Y, Li L, Liou HC, Greene MI, Tone M, Chen YH. 2009. Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 31:932-940. doi: 10.1016/j.immuni.2009.10.006.
61. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. 2011. Regulatory Tcell responses to low-dose interleukin-2 in HCV-induced vasculitis. The New England Journal of Medicine 365: 2067-2077. doi: 10.1056/NEJMoa1105143.
62. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proceedings of the National Academy of Sciences of USA 105:7797-7802. doi: 10.1073/pnas. 0800928105.
63. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9:671-675. doi: 10.1038/nmeth.2089.
64. Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B, Sahota G, Sim J, Mukasa R, Cemerski S, Hatton RD, Stormo GD, Weaver CT, Russell JH, Murphy TL, Murphy KM. 2009. The AP-1 transcription factor Batf controls T (H)17 differentiation. Nature 460:405-409. doi: 10.1038/nature08114.
65. Shaw SY, Tran K, Castoreno AB, Peloquin JM, Lassen KG, Khor B, Aldrich LN, Tan PH, Graham DB, Kuballa P, Goel G, Daly MJ, Shamji AF, Schreiber SL, Xavier RJ. 2013. Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chemical Biology 8:2724-2733. doi: 10.1021/ cb400352d.
66. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. 2013. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569-573. doi: 10.1126/science.1241165.
67. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of USA 102:15545-15550. doi: 10.1073/pnas.0506580102.
68. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. 2007. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. The Journal of Experimental Medicine 204:1775-1785. doi: 10.1084/jem.20070602.
69. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. 2004. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. The Journal of Experimental Medicine 199:1467-1477. doi: 10.1084/jem.20040180.
70. Ulivieri C, Baldari CT. 2014. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacological Research 88:41-52. doi: 10.1016/j.phrs.2014.03.001.
71. Vaeth M, Schliesser U, Müller G, Reissig S, Satoh K, Tuettenberg A, Jonuleit H, Waisman A, Müller MR, Serfling E, Sawitzki BS, Berberich-Siebelt F. 2012. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of USA 109:16258-16263. doi: 10.1073/pnas.1203870109.
72. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B. 2008. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:106-109. doi: 10.1038/nature06881.
73. von Boehmer H, Daniel C. 2012. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nature Reviews Drug Discovery 12:51-63. doi: 10.1038/nrd3683.
74. Wippich F, Bodenmiller B, Trajkovska MG, Wanka S, Aebersold R, Pelkmans L. 2013. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell 152:791-805. doi: 10.1016/j.cell. 2013.01.033.
75. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, Regev A, Kuchroo VK. 2013. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496:513-517. doi: 10.1038/nature11984.
76. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A. 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126:375-387. doi: 10.1016/j.cell.2006.05.042.
77. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, Kuchroo VK. 2008. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL- 23 receptor expression. The Journal of Immunology 181:2277-2284. doi: 10.4049/jimmunol.181.4.2277.
78. Xiao S, Yosef N, Yang J, Wang Y, Zhou L, Zhu C, Wu C, Baloglu E, Schmidt D, Ramesh R, Lobera M, Sundrud MS, Tsai PY, Xiang Z, Wang J, Xu Y, Lin X, Kretschmer K, Rahl PB, Young RA, Zhong Z, Hafler DA, Regev A, Ghosh S, Marson A, Kuchroo VK. 2014. Small-molecule RORgt antagonists inhibit t helper 17 cell transcriptional network by divergent mechanisms. Immunity 40:477-489. doi: 10.1016/j.immuni.2014.04.004.
79. Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, Gennert D, Satija R, Shakya A, Lu DY, Trombetta JJ, Pillai MR, Ratcliffe PJ, Coleman ML, Bix M, Tantin D, Park H, Kuchroo VK, Regev A. 2013. Dynamic regulatory network controlling TH17 cell differentiation. Nature 496:461-468. doi: 10. 1038/nature11981.
80. Zhang H, Nestor CE, Zhao S, Lentini A, Bohle B, Benson M, Wang H. 2013. Profiling of human CD4+ T-cell subsets identifies the TH2-specific noncoding RNA GATA3-AS1. The Journal of Allergy and Clinical Immunology 132: 1005-1008. doi: 10.1016/j.jaci.2013.05.033.
81. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. 2008. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Journal of Immunology 180:6988-6996. doi: 10.4049/jimmunol.180.10.6988.
82. Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W, Wan YY. 2012. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. The Journal of Immunology 189:4417-4425. doi: 10.4049/jimmunol.1200919.
83. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY. 2009. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458: 351-356. doi: 10.1038/nature07674.
84. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF Littman DR. 2008. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453:236-240. doi: 10.1038/nature06878.